CoChat
Sign Up
Cited by 31Syphilis Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of LifeReproductive tract infections research

Third-Trimester Prenatal Syphilis Screening: A Cost-Effectiveness Analysis

Albright, Catherine M., Emerson, Jenna B., Werner, Erika F., Hughes, Brenna L.·2015·Obstetrics & Gynecology
DOI 10.1097/aog.0000000000000997
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To estimate the cost to prevent one case of congenital syphilis or fetal or neonatal death with universal third-trimester syphilis rescreening in the United States and to estimate the incidence of syphilis seroconversion at which rescreening becomes cost-effective. METHODS: We created a decision model comparing universal third-trimester syphilis rescreening in women who screened negative in the first trimester with no rescreening. The assumed base case incidence of seroconversion was 0.012%. The primary outcome was the cost to prevent one case of congenital syphilis. Secondary outcomes included the cost to prevent one fetal or neonatal death and the number needed to rescreen to prevent one adverse outcome. A strategy was considered cost-effective if it cost less than $285,000 to prevent one case of congenital syphilis (the estimated long-term care cost). RESULTS: Under our assumptions, universal third-trimester rescreening would cost an additional $419,842 for each case of congenital syphilis prevented and $3,621,144 and $6,052,534, respectively, for each fetal and neonatal death prevented. Rescreening 4,000,000 women would prevent 60 cases of congenital syphilis and seven fetal and four neonatal deaths. Prevention of one case of congenital syphilis would require 65,790 women be rescreened. Seroconversion incidence of 0.017% would make third-trimester rescreening cost-effective. CONCLUSION: Universal third-trimester syphilis rescreening requires a large number of women be rescreened at a high health care cost to prevent one adverse outcome from maternal syphilis. Seroconversion incidence must be 19-fold higher than the national average of primary and secondary syphilis in women for universal third-trimester rescreening to be cost-effective.

Integrity signals

Registry

Crossref · 10.1097/aog.0000000000000997

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Testing in the third trimester and at delivery can prevent congenital syphilis cases.

    “Testing in the third trimester and at delivery can prevent congenital syphilis cases (146,147).”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [147]

Cites

Flagged first, then by citations

1 of the 42 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Albright, C. M., Emerson, J. B., Werner, E. F., & Hughes, B. L.
Affiliations
Brown University (US)
ORCID
Venue
Obstetrics & Gynecology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2015-09
Volume
126
Issue
3
Pages
479-485
ISSN
0029-7844 (ISSN-L)
DOI
10.1097/aog.0000000000000997
OpenAlex
W2329776645
Cited by
31
References
42
Citations by year
2025: 2 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 7 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 2
FWCI
2.21
Type
journal article
Language
en
Open access
closed
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Syphilis Diagnosis and Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
congenital syphilis, prenatal syphilis screening, cost-effectiveness, fetal death, neonatal death, maternal syphilis, decision models
MeSH terms
Cost-Benefit Analysis, Decision Support Techniques, Female, Humans, Infant, Infant Mortality, Mass Screening, Pregnancy, Pregnancy Complications, Infectious, Pregnancy Trimester, Third, Prenatal Care, Prenatal Diagnosis, Syphilis, Congenital, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review